CVS Health (NYSE:CVS) Releases FY 2025 Earnings Guidance

CVS Health (NYSE:CVS) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 5.750-6.000 for the period, compared to the consensus earnings per share estimate of 5.970. The company issued revenue guidance of -.

CVS Health Stock Performance

CVS opened at $66.35 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The firm has a fifty day moving average price of $50.71 and a 200 day moving average price of $55.94. CVS Health has a 1 year low of $43.56 and a 1 year high of $80.75. The stock has a market cap of $83.49 billion, a P/E ratio of 16.84, a P/E/G ratio of 0.60 and a beta of 0.61.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. Equities research analysts anticipate that CVS Health will post 5.14 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.01%. CVS Health’s dividend payout ratio (DPR) is currently 67.51%.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of analyst reports. Leerink Partners upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $55.00 to $75.00 in a research report on Thursday. Wells Fargo & Company upped their price target on shares of CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday. Piper Sandler reduced their price target on shares of CVS Health from $72.00 to $64.00 and set an “overweight” rating for the company in a research report on Monday, November 25th. TD Cowen upped their price target on shares of CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Finally, Leerink Partnrs upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $70.28.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.